In-Depth Forecast & Analysis on Carcinoid Syndrome Diarrhea Treatment Market for 2017 - 2025
Verfasser: yogesh on Monday, 17 December 2018Carcinoid syndrome is a group of symptoms that can occur in patients suffering from carcinoid tumors which also called as metastatic neuroendocrine tumors. Carcinoid tumors are rare and these are slow growing tumors. Most of the tumors occur in gastrointestinal tract. According to FDA, carcinoid syndrome occurs in less than 10 percent of people suffering from carcinoid tumors, mostly after the tumor has spread to the liver. This syndrome causes overproduction of serotonin hormone which results in chronic diarrhea. Chronic diarrhea leads to malnutrition, weight loss, electrolyte imbalance and dehydration. Carcinoid syndrome diarrhea can be managed either by blocking action of serotonin or by reducing the production of serotonin hormone.
Carcinoid Syndrome Diarrhea Treatment Market: Drivers and Restraints
Carcinoid syndrome diarrhea is a rare condition. Treatment available for this condition are expected to get orphan drug status. Government and regulatory body support for development of orphan drug and incentives are expected to drive carcinoid syndrome treatment market. Government allow companies to set high price for the orphan drug and which in turn will generate high revenue. Ineffectiveness of diarrhea controlling agents in case of carcinoid syndromes diarrhea will also drive the growth of this market. Lower adoption of carcinoid syndrome diarrhea treatment in developing nations can restrict the market growth.